Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Intra-Cellular Therapies Inc (ITCI) USD0.0001

Sell:$13.91 Buy:$13.92 Change: $0.24 (1.70%)
NASDAQ:1.39%
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Sell:$13.91
Buy:$13.92
Change: $0.24 (1.70%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Sell:$13.91
Buy:$13.92
Change: $0.24 (1.70%)
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Contact details

Address:
430 E 29th St
NEW YORK
10016-8367
United States
Telephone:
+1 (212) 9233344
Website:
www.intracellulartherapies.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ITCI
ISIN:
US46116X1019
Market cap:
$689.73 million
Shares in issue:
55.13 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Lawrence Hineline
    Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
  • Michael Halstead
    Executive Vice President, General Counsel and Secretary
  • Mark Neumann
    Executive Vice President, Chief Commercial Officer
  • Andrew Satlin
    Executive Vice President and Chief Medical Officer
  • Robert Davis
    Senior Vice President and Chief Scientific Officer
  • John Bardi
    Senior Vice President - Market Access, Policy and Government Affairs
  • Suresh Durgam
    Senior Vice President, Late Stage Clinical Development and Medical Affairs
  • Michael Olchaskey
    Senior Vice President, Head of Regulatory Affairs
  • Kimberly Vanover
    Senior Vice President, Early Stage Clinical Development and Translational Medicines
  • Sharon Mates
    Chairman of the Board, President, Chief Executive Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.